Firstly, we demonstrated that ruxolitinib or fedratinib treatment reduced STAT5 tyrosine phosphorylation in a dose-dependent manner in HPV+ cervical cancer cells (Figure 4E). Here, STAT5B is linked to cervical carcinoma.